Gazelle COVID-19 Test Clinical Accuracy Protocol
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: PRIYA THOTA, MD
- Phone Number: 2162339405
- Email: p.thota@hemexhealth.com
Study Contact Backup
- Name: David Bell, MD
- Email: d.bell@hemexhealth.com
Study Locations
-
-
Washington
-
Bellingham, Washington, United States, 98226
- Recruiting
- Northwest Pathology drive thru site, Bellingham International Airport
-
Contact:
- Bri Spencer
- Email: Bri.Spencer@nwlaboratory.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Symptomatic study:
Inclusion Criteria:
The presence of clinical signs and symptoms consistent with COVID-19. Signs and symptoms include:
- Fever
- Coughing
- Shortness of breath
- Recent loss of sense of smell or taste
- Chills
- Repeated shaking with chills
- Muscle pain
- Headache
- Sore throat
Vomiting or diarrhea
- Within 1-5 days of symptom onset
- Informed consent for all the samples will be obtained from the subject or obtained from the parent/guardian in case the patient is a minor
- All ages
- All genders
- Pregnant women
Exclusion Criteria:
- Severe disease requiring immediate medical intervention
- Inability to tolerate sampling procedure (nasal swab)
- Failure to provide informed consent
- Nasal deformities preventing sampling by swab
- Ongoing nosebleeds or use of a nasal spray within the last 4 hours.
- Asymptomatic patients
Asymptomatic study:
Inclusion criteria:
- Present to the facility for a COVID-19 test without symptoms
- Informed consent for all specimens will be obtained from the patient or obtained from the parent/guardian in case the patient is a minor
Exclusion Criteria:
Exclusion criteria include one or more of the following:
- Severe disease requiring immediate medical intervention
- Inability to tolerate sampling procedure
- Is below 2 years old
- Failure to provide informed consent
- Nasal deformities preventing sampling by swab
- Ongoing nosebleeds or use of a nasal spray within the last 4 hours.
- Presence of typical symptoms of COVID-19 (fever, sore throat, fatigue, etc.)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Positive percent agreement and negative percent agreement of the Gazelle COVID-19 Test compared to Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) will be measured
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Sensitivity and specificity on at least 30, maximum 65, SARS-CoV-2 positive patient samples will be assessed
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ryan Robert Fortna, MD, PhD, Northwest Pathology
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GZL-FC10-PTL-0001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.